SeQuent Scientific Ltd - Stock Investment Idea Weekly Pick

SeQuent Scientific Ltd is showing strong swing trading opportunity as it forms a higher-bottom structure with rising volumes, supported by a breakout from a multi-year Cup & Handle pattern. Super-trend and MACD are bullish and RSI stays above 60, indicating sustained upside momentum. Traders may accumulate in 230–245 zone for potential targets of 300–325 with stop loss below 195 (closing basis).

Expert recommendation by Mr. Ketan Kaushik - Derivative Analyst (NISM - 202200162803)

• Current Price: 239
• Buying Price: 230-245
• Target Price: 300-325
• Stop loss: 195
• Upside: 36%
• Time Frame: 10-12 Weeks

Stock Technical Analysis

• The stock witnessed a sharp up-move and made an all-time high of 336 in June 2021. After making this high, it corrected and entered a consolidation phase. The stock is now forming a higher-bottom structure on the weekly timeframe, supported by rising volume activity.
• The price structure is developing a large four-year Cup & Handle pattern and has registered a breakout above the long-term descending trendline with strong volume support.
• The trend-following indicator Super-trend is indicating bullish bias both on daily and weekly timeframes, indicating positive multi-timeframe trend alignment.
• The momentum indicator RSI is sustaining comfortably above the 60 level, and MACD remains above the zero line on both the daily and weekly charts, which suggest buying momentum likely to continue in the coming days.

Traders can consider accumulating SEQUENT in the 230–245 zone and look for upside targets of 300–325 over the next 10–12 weeks, with a stop loss below 195 on a closing basis.

💡 Learn to find more such setups with our swing trading guide to stay ahead of market opportunities.

Know more about SeQuent Scientific Ltd

Website: https://sequent.in/

SeQuent Scientific Ltd is India’s largest and one of the world’s leading animal health API and formulation companies, operating through its flagship brand Alivira Animal Health. The company serves more than 100 countries with a diversified portfolio across livestock and companion animal segments. SeQuent operates multiple USFDA-, EU- and WHO-approved manufacturing facilities and continues to expand its global footprint through innovation, regulatory strength and strategic partnerships. With increasing demand for veterinary pharmaceuticals and strong margin improvement visibility, SeQuent remains well-positioned for long-term sustainable growth.

Open your MNCL Demat Account